Canada markets open in 3 hours 36 minutes
  • S&P/TSX

    +64.45 (+0.30%)
  • S&P 500

    -13.86 (-0.25%)
  • DOW

    +299.90 (+0.77%)

    -0.0002 (-0.03%)

    -0.03 (-0.04%)
  • Bitcoin CAD

    -2,083.77 (-2.32%)
  • CMC Crypto 200

    -18.16 (-1.34%)

    +8.00 (+0.34%)
  • RUSSELL 2000

    -7.84 (-0.39%)
  • 10-Yr Bond

    +0.0370 (+0.88%)
  • NASDAQ futures

    -14.00 (-0.07%)

    +0.13 (+0.98%)
  • FTSE

    -61.15 (-0.74%)
  • NIKKEI 225

    -36.55 (-0.09%)

    +0.0004 (+0.06%)

Earnings Estimates Moving Higher for Haemonetics (HAE): Time to Buy?

Haemonetics (HAE) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this provider blood management systems for health care providers and blood collectors, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Haemonetics, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.


The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

The company is expected to earn $0.76 per share for the current quarter, which represents a year-over-year change of +31.03%.

Over the last 30 days, the Zacks Consensus Estimate for Haemonetics has increased 8.57% because three estimates have moved higher compared to no negative revisions.

Current-Year Estimate Revisions

For the full year, the company is expected to earn $3.55 per share, representing a year-over-year change of +17.16%.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Haemonetics. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 8%.

Favorable Zacks Rank

The promising estimate revisions have helped Haemonetics earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

While strong estimate revisions for Haemonetics have attracted decent investments and pushed the stock 7.1% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Haemonetics Corporation (HAE) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research